Drug
JSP191
JSP191 is a pharmaceutical drug with 3 clinical trials. Currently 2 active trials ongoing.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Completion Rate
0%(0/1)
Active Trials
2(67%)
Terminated
1(33%)
Phase Distribution
Ph phase_1
2
67%
Ph early_phase_1
1
33%
Phase Distribution
3
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Early Phase 1First-in-human
1(33.3%)
Phase 1Safety & dosage
2(66.7%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
0.0%
0 of 1 finished
Non-Completion Rate
100.0%
1 ended early
Currently Active
2
trials recruiting
Total Trials
3
all time
Status Distribution
Active(2)
Terminated(1)
Detailed Status
Terminated1
Recruiting1
Active, not recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
2
Success Rate
0.0%
Most Advanced
Phase 1
Trials by Phase
Early Phase 11 (33.3%)
Phase 12 (66.7%)
Trials by Status
terminated133%
recruiting133%
active_not_recruiting133%
Recent Activity
2 active trials
Showing 3 of 3
recruitingphase_1
Depleted Donor Stem Cell Transplant in Children and Adults With Fanconi Anemia After Being Conditioned With a Regimen Containing Briquilimab
NCT04784052
active_not_recruitingearly_phase_1
Study to Assess the Use of JSP191 in Matched Unrelated Donor Transplantation for Chronic Granulomatous Disease (CGD)
NCT05600907
terminatedphase_1
JSP191 (briquilimab) in Subjects with LR-MDS
NCT05903274
Clinical Trials (3)
Showing 3 of 3 trials
NCT04784052Phase 1
Depleted Donor Stem Cell Transplant in Children and Adults With Fanconi Anemia After Being Conditioned With a Regimen Containing Briquilimab
NCT05600907Early Phase 1
Study to Assess the Use of JSP191 in Matched Unrelated Donor Transplantation for Chronic Granulomatous Disease (CGD)
NCT05903274Phase 1
JSP191 (briquilimab) in Subjects with LR-MDS
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3